Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study

Journal of Cardiac Failure

Volumn 15, Issue 8, 2009, Pages 651-657

  Guglin, Maya ^a   Hartlage, Gregory ^a   Reynolds, Christopher ^a   Chen, Ren ^a   Patel, Vinod ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

cardiomyopathy; chemotherapy; heart failure; Trastuzumab

Indexed keywords

TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; DRUG WITHDRAWAL; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARDIOMYOPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 70349337359     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.04.011     Document Type: Article

References (24)

1. Klein P.M., and Dybdal N. Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol 30 (2003) 49-53
2. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 (2002) 1215-1221
3. Perez E.A., and Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22 (2004) 322-329
4. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
5. Tripathy D., Seidman A., Keefe D., Hudis C., Paton V., and Lieberman G. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 5 (2004) 293-298
6. Leyland-Jones B., Gelmon K., Ayoub J.P., et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21 (2003) 3965-3971
7. Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24 (2006) 4107-4115
8. Gori S., Colozza M., Mosconi A.M., et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 90 (2004) 36-40
9. Esteva F.J., Valero V., Booser D., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 1800-1808
10. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
11. Kelly H., Kimmick G., Dees E.C., et al. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 7 (2006) 237-243
12. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
13. Bria E., Cuppone F., Fornier M., et al. Cardiomyopathy and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 109 (2008) 231-239
14. Ewer M.S., and O'Shaughnessy J.A. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 7 (2007) 600-607
15. Bengala C., Zamagni C., Pedrazzoli P., et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 94 (2006) 1016-1020
16. Bhimaraj A.S.S., Johnson S., Kelly R., and Lad T. Trastuzumab mediated cardiac dysfunction in the clinical setting. J Cardiac Fail 14 (2008) S82
17. Papaldo P., Fabi A., Ferretti G., et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol 17 (2006) 630-636
18. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 (2005) 7811-7819
19. Burris III H., Yardley D., Jones S., et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 22 (2004) 1621-1629
20. Mackey J.R., Clemons M., Cote M.A., et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 15 (2008) 24-35
21. de Korte M.A., de Vries E.G., Lub-de Hooge M.N., et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiomyopathy. Eur J Cancer 43 (2007) 2046-2051
22. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiomyopathy: new insights based on clinical course and response to medical treatment. J Clin Oncol 23 (2005) 7820-7826
23. Telli M.L., Hunt S.A., Carlson R.W., and Guardino A.E. Trastuzumab-related cardiomyopathy: calling into question the concept of reversibility. J Clin Oncol 25 (2007) 3525-3533
24. Jones L.W., Haykowsky M., Peddle C.J., et al. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev 16 (2007) 1026-1031